Press release
Hodgkin's Lymphoma Pipeline Expands as 15+ Pharma Companies Advance 20+ Novel Therapies Toward Market Entry, Finds DelveInsight
Hodgkin's Lymphoma - Pipeline Insight, 2026
DelveInsight's "Hodgkin's Lymphoma - Pipeline Insight, 2026" report provides comprehensive insights about 15+ companies developing several pipeline drugs in the Hodgkin's Lymphoma pipeline landscape. It covers the Hodgkin's Lymphoma pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.
Explore the latest breakthroughs in the Hodgkin's Lymphoma treatment landscape. Learn more about the evolving Hodgkin's Lymphoma pipeline today @ https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr
Key Takeaways from the Hodgkin's Lymphoma Pipeline Report
*
DelveInsight's Hodgkin's Lymphoma Pipeline Insight report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Hodgkin's Lymphoma treatment.
*
The leading Hodgkin's Lymphoma companies include Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics, and others.
*
The companies which have their Hodgkin's Lymphoma drug candidates in the most advanced stage include Affimed Therapeutics, which is evaluating AFM13 in Phase II clinical trials.
*
AFM13 by Affimed Therapeutics is a first-in-class innate cell engager (ICE Registered ) designed to activate the innate immune system against CD30-positive hematologic tumors, currently in Phase II clinical evaluation for Hodgkin's Lymphoma.
*
AUR105 by Aurigene Oncology, a small molecule targeting PRMT5, is in Phase I clinical evaluation for Hodgkin's Lymphoma, with potential across multiple hematologic malignancies.
*
The Hodgkin's Lymphoma pipeline features therapies spanning multiple mechanisms including checkpoint inhibitors, antibody-drug conjugates, targeted small molecules, and innate immune cell engagers, reflecting diversified R&D approaches.
*
Global coverage is provided in the Hodgkin's Lymphoma Pipeline Insight, 2026 report, encompassing late-stage, mid-stage, early-stage, preclinical, and discovery-stage pipeline products.
Download for updates and the latest revolution in Hodgkin's Lymphoma care @ Hodgkin's Lymphoma Market Insight [https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Hodgkin's Lymphoma Emerging Drugs Profile
* AFM13: Affimed Therapeutics
AFM13 is a first-in-class innate cell engager (ICE Registered ) that uniquely activates the innate immune system to destroy CD30-positive hematologic tumors. AFM13 induces specific and selective killing of CD30-positive tumor cells, leveraging the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages. AFM13 is a tetravalent bispecific innate cell engager designed to act as a bridge between the innate immune cells and the tumor, creating the necessary proximity for the innate immune cells to specifically destroy the tumor cells. The most advanced ICE Registered clinical program, AFM13 was evaluated as monotherapy in a Phase IIB trial (REDIRECT) in patients with relapsed/refractory peripheral T cell lymphoma, achieving an ORR of 32.4% with a well-managed safety profile. Currently, AFM13 is in Phase II stage of clinical trial evaluation for the treatment of Hodgkin's Lymphoma.
* AUR105: Aurigene Oncology
AUR105 is a small molecule that acts by targeting protein arginine methyltransferase 5 (PRMT5). The drug candidate is also under development for other indications including solid tumors, non-Hodgkin lymphoma, and leukemia. AUR105 is administered through the oral route, offering a convenient dosing option for patients. Currently, the drug is being evaluated in Phase I for the treatment of Hodgkin's Lymphoma.
For more information on the Hodgkin's Lymphoma Emerging Drugs Profile, download DelveInsight's comprehensive Hodgkin's Lymphoma Pipeline Insight report @ Hodgkin's Lymphoma Emerging Drugs [https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
The Hodgkin's Lymphoma Pipeline Report Provides
*
Detailed insights about companies developing therapies for Hodgkin's Lymphoma, with aggregate therapies developed by each company.
*
Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Hodgkin's Lymphoma treatment.
*
Hodgkin's Lymphoma companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Hodgkin's Lymphoma drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Hodgkin's Lymphoma market.
Learn more about Hodgkin's Lymphoma drug opportunities in our comprehensive pipeline report @ Hodgkin's Lymphoma Unmet Needs [https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Hodgkin's Lymphoma Companies
There are 15+ key companies, such as Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics, and others, developing therapies for Hodgkin's Lymphoma, with Affimed Therapeutics having its Hodgkin's Lymphoma drug candidate AFM13 in the most advanced Phase II stage.
DelveInsight's Hodgkin's Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical
Hodgkin's Lymphoma products have been categorized under various Molecule types such as:
*
Monoclonal Antibody
*
Peptides
*
Polymer
*
Small Molecule
*
Gene Therapy
Discover the latest advancements in Hodgkin's Lymphoma treatment by visiting our website. Stay informed @ Hodgkin's Lymphoma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Scope of the Hodgkin's Lymphoma Pipeline Report
*
Coverage: Global
*
Hodgkin's Lymphoma Companies: Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics, and others
*
Hodgkin's Lymphoma Therapies: AFM13, AUR105, and other pipeline candidates across Phase III, Phase II, Phase I, preclinical, and discovery stages
*
Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
*
Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Table of Contents
*
Introduction
*
Executive Summary
*
Hodgkin's Lymphoma: Overview
*
Pipeline Therapeutics
*
Therapeutic Assessment
*
Hodgkin's Lymphoma - DelveInsight's Analytical Perspective
*
Late Stage Products (Phase III)
*
Mid Stage Products (Phase II)
*
Early Stage Products (Phase I)
*
Preclinical and Discovery Stage Products
*
Inactive Products
*
Hodgkin's Lymphoma Key Companies
*
Hodgkin's Lymphoma Key Products
*
Hodgkin's Lymphoma Unmet Needs
*
Hodgkin's Lymphoma Market Drivers and Barriers
*
Hodgkin's Lymphoma Future Perspectives and Conclusion
*
Hodgkin's Lymphoma Analyst Views
*
Appendix
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hodgkins-lymphoma-pipeline-expands-as-15-pharma-companies-advance-20-novel-therapies-toward-market-entry-finds-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hodgkin's Lymphoma Pipeline Expands as 15+ Pharma Companies Advance 20+ Novel Therapies Toward Market Entry, Finds DelveInsight here
News-ID: 4428673 • Views: …
More Releases from ABNewswire
Projecting the Global Needle Safety Devices Market Size to Expand at a 5.39% CAG …
Needle Safety Devices Market Insights, Competitive Landscape, and Market Forecast - 2034" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers.
As per DelveInsight's assessment, The expansion of the needle safety devices market is primarily driven by the growing incidence of accidental needlestick injuries and increased awareness of blood-borne infection risks among healthcare workers. Additionally, the rising prevalence of chronic diseases requiring frequent injections,…
Novartis's COSENTYX (Secukinumab) Approved by the FDA for Pediatric Hidradenitis …
DelveInsight Analysis: What Novartis's COSENTYX (Secukinumab) Approval by the FDA for Pediatric Hidradenitis Suppurativa Means for the Hidradenitis Suppurativa Treatment Market, Biologic Competition, and Commercial Strategy?
On March 13, 2026, Novartis announced that the FDA granted approval for COSENTYX (secukinumab) for the treatment of moderate to severe hidradenitis suppurativa (HS) in pediatric patients aged 12 years and older weighing at least 30 kg. The approval marks the fourth pediatric indication for…
Mammography Devices Market Poised for Robust Growth at 8.25% CAGR Through 2034: …
The global mammography devices market is set for strong, sustained expansion, driven by companies such as, SternMed GmbH, FUJIFILM Corporation, Hologic Inc., Planmed OY, General Electric Company (GE Healthcare), Siemens Healthcare GmbH, Koninklijke Philips NV, DMS Group, IMS Giotto S.P.A, General Medical Merate S.p.A, Konica Minolta Inc., Lanmage, Crestream Health, MEDI-FUTURE Inc. and others.
The global mammography devices market is set for strong, sustained expansion, driven by rising breast cancer incidence,…
Fetal Monitoring Devices Market Set for Steady Growth at 6.34% CAGR Through 2034 …
The global fetal monitoring devices market is set for strong, sustained expansion, driven by companies such as General Electric Company (GE Healthcare), Koninklijke Philips N.V., FUJIFILM Holdings Corporation, Cardinal Health, Inc., Siemens Healthcare GmbH, Natus Medical Incorporated, Huntleigh Healthcare Limited, Clinical Computer Systems, Inc., Edan Instruments, Inc., Neoventa Medical AB, Arjo, Bionet, Contec Medical Systems Co., Ltd. and others.
The global fetal monitoring devices market is set for strong, sustained expansion,…
More Releases for Hodgkin
Hodgkin Lymphoma Treatment Market Poised to Reach USD 15.70 Bn by 2030 at 8.3% C …
Opening Paragraph
According to a new report by Maximize Market Research, the global Hodgkin Lymphoma Treatment Market was valued at USD 8.98 billion in 2023 and is projected to reach nearly USD 15.70 billion by 2030, growing at a CAGR of 8.3%.
Curious to peek inside? Grab your sample copy of this report now:https://www.maximizemarketresearch.com/request-sample/124690/
Key Highlights
Market Size & CAGR: Valued at USD 8.98 Bn in 2023, forecast to grow to USD 15.70…
High Prevalence Of Non-Hodgkin Lymphoma Fuels Market Growth: The Driving Engine …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Non Hodgkin Lymphoma (NHL) Market Size Growth Forecast: What to Expect by 2025?
The market size for non hodgkin lymphoma (NHL) has consistently seen robust growth in recent times. It is anticipated to expand from $10.11 billion in 2024 to $11.01 billion in 2025, with a compound annual growth…
Breakthrough Treatments for Non-Hodgkin Lymphoma
The Business Research Company recently released a comprehensive report on the Global Non Hodgkin Lymphoma (NHL) Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The non hodgkin…
Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight
The market for Non Hodgkin Lymphoma has significant unmet medical necessities in terms of demand for innovative drugs and novel technologies. This is one of the major factors behind the market witnessing rapid growth in Non Hodgkin Lymphoma segment. Past few decades have witnessed an increased level of activity with regards to development of new identification systems and drug mechanisms. In recent years, there have been an increasing number of…
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017 | Market R …
Market Research Hub (MRH) has recently published a latest market study to its online portal, which is titled as “Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017” This study offers professional analysis of the current state of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Market.
Request Free Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1049067
Market Research HUB’s latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Pipeline Review, H1 2017, provides…
Non-Hodgkin Lymphoma - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Non-Hodgkin Lymphoma - Heat Map and Analysis to its growing collection of premium market research reports.
Non-Hodgkin lymphomas (NHL) are a heterogeneous group of malignancies that originate from lymphoid tissue, with varied clinical and biological features. There were an estimated 385,741 new cases of NHL and 199,630 deaths from NHL worldwide in 2012. NHLs are classified as either indolent (slow-growing)…
